PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield
New Jersey
07080-2449
United States
Tel: 908-222-7000
Fax: 908-222-7231
Website: http://www.ptcbio.com/
300 articles with PTC Therapeutics, Inc.
-
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2018 Financial Results
5/1/2018
PTC Therapeutics, Inc. announced that the Company will host a webcast conference call to report its first quarter 2018 financial results and provide an update on the company's business and outlook on Wednesday, May 9, 2018 at 4:30 p.m. (ET) after closing of the market.
-
PTC Therapeutics to Participate at Upcoming Investor Conference
4/30/2018
PTC Therapeutics, Inc. announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health Care Conference, on Tuesday, May 15th at 2:20 p.m.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Approved April 24, 2018
4/27/2018
PTC Therapeutics, Inc. announced that on April 24, 2018 it approved non-statutory stock options to purchase an aggregate of 172,150 shares of its common stock to 25 new employees and a restricted stock unit for 4,000 shares of its common stock to one of the new employees.
-
PTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs
4/9/2018
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York City. Members of PTC's senior management and research teams will provide a corporate update and in-depth reviews of the Company's commercial products, scientific platforms and R&D programs
-
PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease
4/4/2018
The program is optimizing small-molecule compounds--identified using PTC's splicing technology platform--that decrease the production of huntingtin protein.
-
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
3/29/2018
PTC Therapeutics, Inc. announced the pricing of a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share, before underwriting discounts.
-
PTC Therapeutics Announces Proposed Public Offering of Common Stock
3/27/2018
PTC Therapeutics, Inc. announced that it is commencing a public offering of 4,000,000 shares of its common stock.
-
Technical Perspectives on Biotech Stocks -- PTC Therapeutics, Regeneron Pharma, Ritter Pharma, and Sangamo Therapeutics
3/5/2018
WallStEquities.com strives to bring the best free research to the investment community is offering reports on PTCT, REGN, RTTR, and SGMO which can be accessed for free by signing up to www.wallstequities.com/registration.
-
PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs
2/20/2018
The FDA has denied PTC Therapeutics appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for ataluren.
-
PTC Therapeutics Release: Preliminary Data From FIREFISH Trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy
1/29/2018
FIREFISH is a two-part seamless, open-label, multi-center study to investigate the safety and efficacy of RG7916 in infants and babies with Type 1 SMA.
-
The company believes the Translarna data is compelling and pointed to the success the drug is having in Europe.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
1/8/2018
The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
-
PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities
1/8/2018
PTC Therapeutics today provided a corporate update, which will be detailed as part of the company's presentation at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th at 2:30 pm PT.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) of 10,000 Shares of Its Common Stock
12/18/2017
The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
-
PTC Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/21/2017
The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
-
PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/3/2017
Translarna net product sales were $32.0 million for the third quarter of 2017, representing 45% growth over $22.0 million reported in the third quarter of 2016.
-
This is the third time the FDA has rejected the drug.
-
Big pharmas are having a good year so far in terms of FDA approvals.
-
PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results
10/19/2017
PTC Therapeutics today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Thursday, November 2, 2017 at 4:30 p.m. (ET) after the closing of the market.
-
PTC Therapeutics Release: Spinal Muscular Atrophy Program Advances Into Pivotal Study In SMA Patients
10/12/2017